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Abstract 
 
Objective: Synaptic dysfunction is linked to both Alzheimer’s disease (AD) and major depressive disorder 
(MDD). Synapse protein concentrations in cerebrospinal fluid (CSF) may be useful biomarkers to monitor 
synaptic dysfunction and degeneration that lead to depressive symptoms and AD, respectively. CSF 
neurogranin (Ng), a post-synaptic protein, has emerged as a promising tool to detect synaptic dysfunction 
and/or loss in AD. The aim of this study was to test the specific hypothesis that CSF neurogranin (Ng) is able 
to differentiate AD from MDD and cognitively normal controls. 
Method: CSF samples from 44 healthy control individuals (CTRL) and 86 mild cognitive impairment (MCI, 
36 of whom had prodromal AD, as defined by a positive CSF AD biomarker signature), 25 AD and 6 MDD 
subjects were analyzed using an in house enzyme-linked immunosorbent assay (ELISA) for Ng. 
Results: CSF Ng levels were significantly higher in AD patients and in prodromal AD (MCI patients with an 
“AD-like” CSF tau and A42 profile) compared with CTRL individuals (p<0.0001 for both groups) and 
MDD patients (p<0.001 and p<0.01, respectively). Significantly higher CSF Ng concentration was also seen 
in prodromal AD patients as compared to  MCI patients without biomarker evidence of underlying AD 
pathology (p<0.0001). CSF Ng correlated positively with the classical axonal injury markers CSF T-tau and 
P-tau (p<0,0001), whereas correlation to plaque pathology as reflected by CSF A42 was less clear. 
Negative correlations of CSF Ng with cognitive evaluation scores (MMSE and CAMCOG) were observed.  
Conclusion: This study strengthens the clinical utility of CSF Ng as a CSF biomarker for AD. AD patients 
in both MCI and dementia stages of the disease had increased CSF Ng concentrations compared with 
cognitively normal control individuals, patients with non-AD MCI and patients with MDD. The lowest CSF 
Ng concentrations were seen in patients with MDD, a finding that warrants validation in further studies.  
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Abbreviations: AD= Alzheimer’s disease; Aβ= amyloid-β; CAMCOG= Cambridge Cognition Examination; 
CaM= calmodulin; CSF= cerebrospinal fluid; CTRL= healthy control; MCI= Mild Cognitive Impairment; 
MDD= Major Depression Disorders; MMSE= Mini Mental State Examination; Ng= neurogranin; p-Tau= 
hyperphosphorylated tau; Tau= total tau;  
 
1. Introduction 
 
Alzheimer’s disease (AD) is the most common neurodegenerative disorder. It is characterized by 
pathological hallmarks including neuronal and synaptic degeneration and loss together with deposits of 
aggregated amyloid-β (Aβ) and tau1. Lower cerebrospinal fluid (CSF) concentrations of the 42 amino acid–
long Aβ peptide Aβ1–42, reflecting the plaque pathology, together with increased concentrations of total tau 
(T-tau) and phosphorylated tau (P-tau), reflecting neurodegeneration and tangle pathology, respectively, are 
today considered the core CSF biomarkers for AD1. Synaptic loss has been identified as an early event in the 
disease progression, as well as the underlying cause of the progressive cognitive deterioration as the disease 
advances2, and recently CSF neurogranin (Ng), a post-synaptic protein that is enriched especially in dendritic 
spines, has emerged as a promising tool to detect synaptic dysfunction and/or loss in AD. CSF Ng 
concentrations are increased in AD, already in the pre-dementia (mild cognitive impairment, MCI) stage of 
the disease, and correlate with hippocampal atrophy and cognitive decline over time3-10. Across 
neurodegenerative diseases CSF Ng increase seems to be specific to AD11  
 
Here, we aimed at replicating the association of CSF Ng with AD in a mono-centre cohort of well-
characterised AD patients in different stages of the disease. We also report, for the first time, CSF Ng 
concentrations in patients with major depressive disorder (MDD), a common differential diagnosis to AD, 
which also may involve synaptic dysfunction12  
 
2. Materials and Method 
2.1 Study population 
CSF samples from patients recruited in the Department of Psychiatry, University of Sao Paulo, Sao Paulo 
Brazil were collected during a period of 4 years. Patients diagnosed with AD fulfilled the dementia criteria of 
the Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revision, and the criteria for 
probable AD as defined by NINCDS-ADRDA13. We re-selected a cohort of the patients where we included 
44 healthy control (CTRL), 86 mild cognitive impairment (MCI), 25 AD, 6 MDD subjects (see Table 1 for 
full biomarker and demographic characteristics) discriminated by using a cut off established by a ROC curve 
towards Aβ1-42 (<390 pg/ml with a Se=64% and Spe=68% with a Youden index=0.9714) and T-tau level (>84 
pg/ml with a Se=68% and Spe=68% with a Youden Index=114). Applying this cut-off in the MCI group we 
observed a clear separation in two groups, according CSF biomarkers profile, one closer to the CTRL profile 
(MCI=50) and the other one closer to the AD profile (prodromal AD=36). All individuals underwent brain 
imaging, routine laboratory testing and neurological, psychiatric and cognitive examinations. The study was 
approved by the local ethics committee (University of Sao Paulo). All subjects gave written informed 
consent. The study was conducted according to the provisions of Declaration of Helsinki. For details on the 
number of cases in each diagnostic group, the demographic and clinical characteristics see Table 1A. 
 
2.2 Cognitive assessments 
Global cognition was assessed by Mini Mental State Examination (MMSE)15 and Cambridge Cognition 
Examination (CAMCOG)16. 
 2.3 Cerebrospinal fluid collection and biomarker analysis 
Patients consented to undergo lumbar puncture for CSF sampling and biomarker analysis. CSF samples were 
taken by lumbar puncture in the L3/L4 or L4/L5 intervertebral space, with a 23-gauge needle and using 
polypropylene tubes, in the morning. A total of 12–15 ml of CSF was collected and, then, centrifuged at 
3200g for 10min at 4 °C. After centrifugation, the samples were separated in 0.5ml aliquots, and 
immediately frozen at −80 °C until analysis. 
The determination of CSF concentrations of AD-related biomarkers (T-tau, P-tau and Aβ1-42), was done in 
duplicate with the INNo-Bia AlzBio3 assay (Innogenetics, Ghent, Belgium), a multiplex microsphere-based 
Luminex (xMAP) platform that allows the simultaneous analysis of these biomarkers. These analyses were 
performed at the University of Sao Paulo. CSF Ng measurement was performed by board-certified 
laboratory technicians who were blinded to clinical information using an in house ELISA, as previously 
described in detail3.  
 
3. Statistical analysis 
For statistical analysis, Prism 7 for Mac software (GraphPad Software, La Jolla, CA, USA) and SPSS 20.0 
for Mac were used. Based on Shapiro-Wilk test, almost all data were skewed, so nonparametric tests were 
used. Differences between groups were assessed using the Mann–Whitney U test, and Kruskal-Wallis test 
was performed to compare data between all groups. Correlations were determined using Spearman’s ρ 
correlation. All tests were two-sided and significance was determined at P < 0.05. Association between the 
levels of CSF Ng, the other CSF biomarkers and the diagnostic groups were tested with linear regression.  
4. Results 
4.1 CSF Ng concentrations in different diagnostic groups 
CSF Ng concentrations were significantly higher in AD patients and in patients with prodromal AD (MCI 
patients with an “AD-like” CSF profile) compared to CTRL (p<0.0001 for both groups) and to MDD 
(p<0.001 and p<0.01, respectively). There was also a difference in CSF Ng concentration between patients 
with MCI without biomarker evidence of underlying AD pathology and prodromal AD patients (p<0.0001), 
confirming that increased CSF Ng concentrations are tightly linked to AD pathology (Table 1A). 
4.2 CSF Ng concentrations in relation to “core AD biomarkers” 
Ng levels showed a strong positive correlation with both T-tau and P-tau (rs=0.68 p<0.0000001; rs= 0.60 
p<0.0000001, respectively). These correlations were also seen when analysing each diagnostic group 
separately (Fig.1 or Table 2), there was a negative correlation with Aβ1-42 (rs= -0.47 p<0,0000001; Table 1B) 
in the whole material, but this potential correlation was not seen in the diagnostic groups, when analysed 
separately (Fig.1 or Table 2).  
4.3 CSF Ng concentrations in relation to clinical characteristics  
Weak negative correlations of CSF Ng with MMSE and CAMCOG were seen in the whole material (rs= -
0.24 p<0.003; rs= 0.23 p<0.004, respectively), but these potential correlations were not significant when 
examined in the diagnostic groups separately (except in AD group rs= -0.40 p<0.05). No significant 
correlation with age (rs= -0.02 p= 0.81) was found (Fig. 3; Table 2). In contrast, CSF Aβ1-42, T-tau and P-tau 
showed weak correlations with age (rs= -0.22 p= 0.009; rs= 0.20 p<0.01, respectively) in the whole material 
(Table 1B) but not within diagnostic groups when tested separately (Fig. 1 or Table 2).  
Discussion 
In the present paper, we show that CSF Ng concentrations are elevated in AD, also in pre-dementia stages of 
the disease. We also corroborate earlier findings that CSF Ng correlates with neurodegeneration and tau 
pathology, as reflected by CSF T-tau and P-tau concentrations17. These markers are, however, also 
influenced by age, a potential confound that does not seem to be that important for CSF Ng, given the lack of 
correlation of CSF Ng with age. Finally, we report for the first time on CSF Ng in MDD. Our cohort only 
included 6 individuals with MDD but all of these had low CSF Ng concentrations. Although the MDD group 
is small and the results need to be replicated in larger numbers of patients, we find it tempting to speculate 
that CSF Ng concentrations may depend both on increased release from degenerating synapses in AD and on 
reduced physiological release from synapses in MDD, which potentially reflects decreased synaptic activity 
in the latter condition. This reduction was not statistically significant when comparing MDD patients with 
healthy controls, which may indicate lack of power due to the small number of MDD patients but the 
reduction in comparison with both AD groups (AD dementia and prodromal AD) was clear. Although the 
MDD results are in need of replication due to the small sample size, our results suggest that AD pathology 
specifically induces abnormal release of Ng into the CSF, which is not seen in MDD. The latter finding, 
although preliminar, underscores the clinical utility of this marker.  
 
 
 
Table 1.  
A) Summary of the demographic, clinical and biomarker data. 
 
  
AD 
 
MCI 
 
Prodromal AD 
 
MDD 
 
CTRL 
 
Gender, m/f, 
(%male) 
 
6/19 (24) 
 
20/30 (40) 
 
14/22 (39) 
 
3/3 (50)  
 
13/31 (29,5) 
Age (yr) 76 (67-85) 71 (68-76)† 73 (71-76) 73 (68-75) 71 (67,5-75)*† 
 
Education (yr) 8 (4-15) 11 (6-16)†† 5 (4-11) 10,5 (4-13,2) 11 (5-15,5)† 
 
MMSE 23 (16,5-26) 28 (26-29)***†† 26,5 (24,2-27)** 28,5 (27-29)**† 29 (27-29)***†† 
 
CAMCOG 74 (59-89) 92 (84-96)***†† 84,5 (80,2-91,5)* 91 (88-94)** 94 (90-97)***†† 
 
Aβ1-42, (pg/ml) 310 (237-355) 554 (448-640)***†† 293 (232-348) 549 (399-673)***†† 529 (481-639)***†† 
 
T-tau, (pg/ml) 144 (102-237) 65 (50-83)***†† 150 (120-209) 69 (46-104)**†† 68 (54-81)***†† 
 
P-tau, (pg/ml) 71 (54-102) 32,5 (25-44)***†† 73 (60-94) 43 (23-55)**†† 35 (26-46)***†† 
 
Ng7, (pg/ml) 687 (474-956) 182,00 (83-310)*** †† 481 (326-841) 144 (76-306)** † 235,50 (171-358)*** †† 
      
 
B) Correlation between demographic, clinical and CSF data. 
A) The values presented are median (IQR). *P<0,5 versus AD; **P<0,01 versus AD; ***P <0,001 versus 
AD; †P <0,05 versus prodromal AD; †† P<0,01 versus prodromal AD.  B) §P<0.01; §§p<0,001; §§§p<0.0001. 
 
 
Rho  
Spearman 
Age Education MMSE CAMCOG Aβ1-42 T-tau P-tau Ng 
         
Age 
(p) 
1 
 
 -0,225§§ 
 
-0,085 
 
-0,137 
 
-0,220§§ 
 
0,204§ 
 
0,12 
 
0,021 
 
Education -0,225§ 
 
1 0,222§§ 
 
0,415§§§ 
 
0,149 
 
-0,256§ 
 
-0,125 
 
-0,14 
MMSE -0,08 
 
0,22§§ 
 
1 0,660§§§ 
 
0,331§§§ 
 
-0,418§§§ 
 
-0,265§§ 
 
-0,244§ 
CAMCOG 
 
-0,137 
 
0,415§§§ 
 
0,660§§§ 
 
1 0,381§§§ 
 
-0,409§§§ 
 
-0,294§§§ 
 
-0,233§ 
 
Aβ1-42 
 
-0,220§§ 
 
0,149 
 
0,331§§§ 
 
0,381§§§ 
 
1 -0,548§§§ 
 
-0,564§§§ 
 
-0,477§§§ 
 
T-tau 
 
0,204§ 
 
-0,256§ 
 
-0,418§§§ 
 
-0,409§§§ 
 
-0,548§§§ 
 
1 0,731§§§ 
 
0,686§§§ 
 
Ptau 
 
0,12 
 
-0,125 
 
-0,265§§ 
 
-0,294§§§ 
 
-0,564§§§ 
 
0,731§§§ 
 
1 0,607§§§ 
 
Ng 
 
-0,021 
 
-0,141 
 
-0,244§ 
 
-0,233§ 
 
-0,477§§§ 
 
0,686§§§ 
 
0,607§§§ 
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Fig. 1 Correlations between Ng and CSF biomarkers; *p<0.05; **p<0.01; ***p<0.001. 
 
I would suggest that you make three panels, one for T-tau, one for P-tau and the last one for Abeta1-42. It 
would be great if AD, prodromal AD, non-AD MCI, controls and MDD patients were indicated by different 
symbols and if the p-values in each diagnostic group were given in the figure legend.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Correlation between Ng, CSF biomarkers and cognitive evaluation scales. 
 
 
Rho 
Spearman 
 
AD 
(n=25) 
 
MCI 
(n=50) 
 
Prodromal AD 
(n=36) 
 
MDD 
(n=6) 
 
CTRL 
(n=44) 
All  
Group 
(n=161) 
 
 
Ng vs Aβ1-42  
 
0.29 
 
 
0.21 
 
 
-0.24 
 
 
-0.25 
 
 
-0.13 
 
 
-0,477*** 
 
 
Ng vs T-tau 
 
 
0.55** 
 
 
0.52*** 
 
 
0.48** 
 
-0.02 
 
 
0.52*** 
 
0,686*** 
 
 
Ng vs P-tau 
 
 
0.43* 
 
 
0.42** 
 
0.64*** 
 
0.25 
 
0.19 
 
0,607*** 
 
 
Ng vs MMSE 
 
 
-0.33 
 
0.14 
 
0.18 
 
0.06 
 
-0.18 
 
-0,244** 
 
 
Ng vs CAMCOG 
 
 
-0.45* 
 
0.26 
 
0.14 
 
0.54 
 
-0.08 
 
-0,233** 
 
*p<0.05; **p<0.01; ***p<0.001. 
 
 
I follow your instructions… “Actually, when looking through these figures, I actually think you should 
simply show CSF Ng with T-tau, P-tau and Abeta42 correlations and put the correlation coefficients and p-
values with cognitive scores into one table where you might also be able to include the correlation 
coefficients within diagnostic groups separately (or mention in the text that they were not significant).” 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References. 
 
1. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma 
biomarkers in Alzheimer disease. Nature reviews Neurology 2010; 6(3): 131-44. 
2. DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: 
correlation with cognitive severity. Annals of neurology 1990; 27(5): 457-64. 
3. Kvartsberg H, Duits FH, Ingelsson M, et al. Cerebrospinal fluid levels of the synaptic 
protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimer's 
& dementia : the journal of the Alzheimer's Association 2015; 11(10): 1180-90. 
4. Kvartsberg H, Portelius E, Andreasson U, et al. Characterization of the postsynaptic protein 
neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and 
healthy controls. Alzheimers Res Ther 2015; 7(1): 40. 
5. Portelius E, Zetterberg H, Skillback T, et al. Cerebrospinal fluid neurogranin: relation to 
cognition and neurodegeneration in Alzheimer's disease. Brain 2015; 138(Pt 11): 3373-85. 
6. Hellwig K, Kvartsberg H, Portelius E, et al. Neurogranin and YKL-40: independent markers 
of synaptic degeneration and neuroinflammation in Alzheimer's disease. Alzheimers Res Ther 2015; 
7(1): 74. 
7. Janelidze S, Hertze J, Zetterberg H, et al. Cerebrospinal fluid neurogranin and YKL-40 as 
biomarkers of Alzheimer's disease. Ann Clin Transl Neurol 2016; 3(1): 12-20. 
8. De Vos A, Jacobs D, Struyfs H, et al. C-terminal neurogranin is increased in cerebrospinal 
fluid but unchanged in plasma in Alzheimer's disease. Alzheimers Dement 2015; 11(12): 1461-9. 
9. Kester MI, Teunissen CE, Crimmins DL, et al. Neurogranin as a Cerebrospinal Fluid 
Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease. JAMA Neurol 2015; 72(11): 
1275-80. 
10. Tarawneh R, D'Angelo G, Crimmins D, et al. Diagnostic and Prognostic Utility of the 
Synaptic Marker Neurogranin in Alzheimer Disease. JAMA Neurol 2016. 
11. Wellington H, Paterson RW, Portelius E, et al. Increased CSF neurogranin concentration is 
specific to Alzheimer disease. Neurology 2016. 
12. Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic 
targets. Science 2012; 338(6103): 68-72. 
13. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis 
of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of 
Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 
34(7): 939-44. 
14. Yin J, Samawi H, Linder D. Improved nonparametric estimation of the optimal diagnostic 
cut-off point associated with the Youden index under different sampling schemes. Biom J 2016. 
15. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading 
the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12(3): 189-98. 
16. Roth M, Tym E, Mountjoy CQ, et al. CAMDEX. A standardised instrument for the 
diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. 
Br J Psychiatry 1986; 149: 698-709. 
17. Thorsell A, Bjerke M, Gobom J, et al. Neurogranin in cerebrospinal fluid as a marker of 
synaptic degeneration in Alzheimer's disease. Brain Res 2010; 1362: 13-22. 
 
